Common Stock and Common Stock Purchase Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	6 Months Ended
	Aug. 08, 2024	Feb. 15, 2024	Jan. 15, 2024	Dec. 07, 2023	Nov. 28, 2023	Feb. 28, 2023	Jun. 30, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split					1-for-15
Common stock, shares authorized							50,000,000	50,000,000
Stock Issused and outstanding description				every 15 shares of the Company’s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares.
Debt instrument fee description							On March 7, 2024, the Company received a notice from the Nasdaq Listing Qualifications Department stating that, for the preceding 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities (“MVLS”) had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The notification letter stated that the Company would be afforded 180 calendar days (until September 3, 2024) to regain compliance. In order to regain compliance, the Company’s MVLS must close at $35 million or more for a minimum of ten consecutive business days.
At-the-market equity facility, shares							333,299
At-the-market equity facility, value							$ 693
Payments for commissions percentage							3.00%
Warrant price decrease		$ 0.52
Share price		0.37709668
Exercise price		$ 23.48
Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price							$ 23.48	$ 23.48
Class of Warrant or Right, Outstanding							11,937,450	11,937,450
Purchase of warrants							795,830	795,830
Exercise price, post reverse-split							$ 24.00	$ 24.00
Number of warrants exercised							0
Lucid Diagnostics Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares		3,331,747	38
Lucid Diagnostics Inc [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares			100
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
At-the-market equity facility, shares	288,067
At-the-market equity facility, value	$ 277
Payments for commissions percentage	3.00%
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible common stock shares issued upon conversion							574,424
Debt Instrument, Convertible, If-converted Value in Excess of Principal							$ 980
Employee Stock Purchase Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock issued							34,332
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-5
Common stock, shares authorized						50,000,000
Minimum [Member] | Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price, post reverse-split							$ 0.52	$ 0.52
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-15
Common stock, shares authorized						250,000,000